Abbott announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.
A University of Iowa physiologist has a new technique to measure the stiffness of the aorta, a common risk factor for heart disease. And it can be as simple as measuring the pulse in your finger. The new procedure works by placing an instrument called a transducer on the finger or over the brachial artery...
Durham, N.C.-based Heart Imaging Technologies won a $2.5 million grant from the National Institutes of Health in support of efforts to build a "corelab of the future." HeartIT pioneered the WebPAX system, which the company calls the 1st FDA-approved zero-footprint medical imaging workstation.
Technology giant Philips awarded a 10-year contract for continuous access of its ultrasound devices to the cardiology department at Medical Center Leeuwarden, a teaching hospital in the Netherlands. The Dutch hospital will also receive training services and periodic structural upgrades as part of the deal.
Manny Villafaña, Chairman and Chief Executive Officer of Kips Bay Medical, Inc., a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery (CABG), provided the following business update to Kips Bay shareholders and the financial community.
Massachusetts-based Asahi Kasei subsidiary Zoll Medical landed a Defense Dept. contract worth up to $210 million, providing defibrillators, monitors, warmers and infusers to multiple divisions of the U.S. armed forces. Zoll beat out 29 other bidders for the contract, according to a DoD report.
New data on Medtronic's Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week. A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.
Students at the Hebrew University Biodesign program develop a handheld device for rapid and safe IV insertion. Biodesign is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and Hadassah Medical Center in partnership with Stanford University.
A new prototype device for rapid and safe IV insertion reduces pain in hospitalized children. The semi-automatic handheld device, called SAGIV, identifies veins, inserts a needle and withdraws it in a single movement. It was developed by students and clinicians in the Biodesign program of the Hebrew University of Jerusalem and Hadassah Medical Center.
IN-TIME Study Shows Significant Reduction in All-Cause Mortality in ICD and CRT-D Patients With BIOTRONIK Home Monitoring(R)September 1, 2013 5:09 am | by The Associated Press | News | Comments
BIOTRONIK, the leading manufacturer of cardiac devices celebrating its 50th anniversary this year, announced ground-breaking results from the IN-TIME study today at the ESC (European Society of Cardiology) congress. Coordinating investigator of IN-TIME, Professor Gerhard...
A sales rep's visit could be worth as much as $230 per case in surgeons' use of coronary stents, according to a study in the American Heart Journal. The presence of a company sales rep in the cath lab increased the likelihood that surgeons would opt for drug-eluting over bare-metal stents, researchers said.
When a beating heart slips into an irregular, life-threatening rhythm, the treatment is well known: deliver a burst of electric current from a pacemaker or defibrillator. But because the electricity itself can cause pain, tissue damage and other serious side-effects, a Johns Hopkins-led research team wants to replace these jolts with a kinder, gentler remedy: light.
St. Jude Medical, Inc., a global medical device company, today announced the CE Mark approval of its next-generation EnligHTN Renal Denervation System for treating patients with drug-resistant, uncontrolled hypertension. The system features an advanced generator that delivers simultaneous ablations via a multi-electrode catheter...
The National Institutes of Health (NIH) has awarded a five-year, $1.94 million grant to a biomedical research team at Worcester Polytechnic Institute (WPI) working at the forefront of cell therapies for healing cardiac muscle damaged by heart attack or chronic disease.
CardioKinetix Announces First Heart Failure Patients Treated in Asia with Minimally Invasive Structural Heart DeviceAugust 29, 2013 8:00 am | by Business Wire | News | Comments
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced a new first with four patients successfully treated this week with the novel catheter-based Parachute ® Ventricular Partitioning Device in Kuala Lumpur, Malaysia.
Within the medical device technology industry, the cardiovascular sector is one of the largest and most stable, due to immediate demand and necessity. As with all areas in the field, engineers continuously strive to design more minimally invasive devices, but with cardiovascular diseases at the top of the list in a growing elderly population, there is an urgent need for continuous advancement.
Cordis Corp., the stent-making arm of Johnson & Johnson, got out of the coronary stent game 2 years go, but that's not stopping Israeli medical device company Medinol from suing Cordis for patent infringement with the Cypher and Cypher Select stents it no longer makes.
Medical device giant Medtronic is handing its Pioneer Plus re-entry catheter product line over to Volcano for an undisclosed amount, the companies announced this week. The deal, which Volcano hopes will help it expand its reach in peripheral indications, is expected to close this month and is structured as an "asset purchase."
Lombard Medical Technologies PLC, the specialist medical technology company focused on innovative vascular products, today announces that the first U.S. patients have been successfully treated with Aorfix, the Group’s flexible stent graft for the endovascular repair of abdominal aortic aneurysms.
Hansen Medical enrolled the 1st 5 patients in a re-designed study to evaluate its robot-assisted atrial fibrillation treatment. The revised study design, which won conditional FDA approval in May, will eventually enroll 125 patients at 14 medical centers to test Hansen's Sensei X robotic catheter system with the company's Artisan control catheters.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE...
Massachusetts-based Abiomed (NSDQ:ABMD) won a lucrative 5-year contract to provide its flagship Impella heart pumps to the Veterans Administration, a deal that could boost the medical device maker's revenue by 20%. Abiomed can provide Impella to about 170 VA medical facilities, more than 40 Defense Dept. hospitals and other federal agencies via an automated online system, according to a company statement.
Volcano Corporation Announces Execution Of Agreement To Purchase Pioneer PlusT Re-Entry Catheter Product Line From MedtronicAugust 26, 2013 4:05 pm | by The Associated Press | News | Comments
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has signed an agreement to acquire the Pioneer PlusT diagnostic ultrasound ...
Starting today, medical device giant Medtronic is banned from selling its CoreValve and CoreValve Evolut transcatheter aortic valve implantation systems in Germany, thanks to a court ruling in favor of rival device maker Edwards Lifesciences.
Irvine, Calif. medical device maker Reverse Medical Corp. touted FDA clearance for its flagship product, the MVP micro vascular plug for peripheral artery embolization. The plug helps decrease blood flow in the peripheral vasculature and is "completely re-sheathable" for use in procedures where a patient needs only temporary blood flow reduction.